Mark Gurney

jamanetwork.com/journals/jamao… Thanks to all involved in our study of baseline factors which associated with subsequent myeloid neoplasms in adult CAR-T recipients. Intuitively, age ≥65 and baseline thrombocytopenia <140 defined the highest risk group in this @MayoClinic cohort.

#BCOR impact in #MN by our group ⁦@Haematologica⁩ ⭐️⬇️ TP53 ⭐️⬆️ U2AF1 RUNX1 ⭐️⬇️ OS regardless of dz ⭐️ HCT ⬆️ OS unless RUNX1+ ⁦@MayoCancerCare⁩ Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms pubmed.ncbi.nlm.nih.gov/38299584/

Huge thank you to @MichaelodwyerMD @ICATProgramme @uniofgalway @clair_gardiner for the opportunity and support and examiners @Ullrich_Lab @aideenryan1 for the engaging viva examination!

TET2 somatic copy number alterations and allelic imbalances in #CMML. sciencedirect.com/science/articl… #4q24 #CNLOH #endoreduplication #TET2 @MarkGurneyOne @ptgcruiser @MayoCancerCare

Abstract submission is open until 25th August. Looking forward to another meeting with high quality contents.

Mpox in solid organ transplant recipients: multicenter case series Mostly kidney recipients. Many with HIV infection. High number of skin lesions. All treated with tecovirimat. One patient died; all others resolved by day 30. @amjtransplant doi.org/10.1016/j.ajt.…

#TP53 allelic status and CN-LOH in #CMML -Infrequent but relevant. Isochromosome 17q with monocytosis associated with poor outcomes @MarkGurneyOne @MayoCancerCare @md_padron @MoffittNews @LashoTerra rdcu.be/dgnPD

Congratulations to Dr. Eibhlin Higgins! After completing ID fellowship in Ireland, she was recruited for the subspecialty Ortho-ID (2022) and Transplant-ID (2023) fellowships at the Mayo Clinic. She will serve as ID consultant at the University Hospital Galway, Ireland.

Our myeloid fellowship is open! This is a 1-year clinical + research program where heme/onc fellows gain additional experience in AML, chronic myeloid disorders, and bone marrow failure syndromes. ECFMG certification required. Visa support is provided. bit.ly/3qvX2cJ

Our paper by ⁦@MarkGurneyOne⁩ on mutated #ETV6 myeloid neoplasms. Should it be one of the secondary mutations? #MDSsm #AMLsm #NGS The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms - Gurney - British Journal of Haematology onlinelibrary.wiley.com/doi/10.1111/bj…

Clinical and Molecular Spectrum and Prognostic Outcomes of U2AF1 Mutan... sciencedirect.com/science/articl… #U2AF1 #Telomeres #Maladaptive #CHIP @DrAlexFerrer @TalhaBadarMD @AlkaliDr @a_mangaonkar @TeamTelomereInc @MayoClinicCIM Stephanie Pritzl

Putting on University of Galway colours for today to share our poster (4603) on TRAIL engineered NK cells with enhanced innate anti-leukemic activity in #AML, at #ASH2022 @MichaelodwyerMD @EvaSzegezdi @margaret_twohig @Eim_OReilly @OnkTherapeutics @ICATProgramme @CancerUniGalway

Looking forward to sharing our poster later today examining the characteristics of ETV6 mutated myeloid neoplasms at #ASH22. Special thanks to @AlkaliDr @ChekkafIsmahene @MayoCancerCare

Made possible through collaboration with @OnkTherapeutics @biotechne and @EvaSzegezdi @nuigalway

The approach was adapted to incorporate CRISPR/Cas9 KO of the NK cell checkpoint CISH delivered in a single electroporation step.

@Eim_OReilly @ICATProgramme @ResearchatNUIG Nice to share our experience of applying the TcBuster transposon system to generate donor derived CLL-1 CAR-NK cells with expression/ expansion/ integration characteristics suited to clinical development for AML.

@sarahcormican91 @ICATProgramme @remedinuig @NUIGalwayMed @mattgriffinneph @hrbireland Huge congrats Sarah & Conor!!